-
1 Comment
Bioventix PLC is currently in a long term downtrend where the price is trading 5.9% below its 200 day moving average.
From a valuation standpoint, the stock is 95.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 20.7.
Finally, its free cash flow fell by 20.9% to $2M since the same quarter in the previous year.
Based on the above factors, Bioventix PLC gets an overall score of 1/5.
| Exchange | LSE |
|---|---|
| CurrencyCode | GBP |
| Sector | Healthcare |
| Industry | Biotechnology |
| ISIN | GB00B4QVDF07 |
| Target Price | 4500 |
|---|---|
| Dividend Yield | 6.3% |
| Beta | 0.52 |
| Market Cap | 133M |
| PE Ratio | 16.89 |
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. It also provides contract SMAs services; and industrial and environmental biomonitoring platform, which reduces the time between sampling and results. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BVXP.LSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
